Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARDN.L Regulatory News (ARDN)

  • There is currently no data for ARDN

Trading Update

1 May 2020 07:00

RNS Number : 5287L
Arden Partners plc
01 May 2020
 

Arden Partners plc

("Arden" or the "Company")

 

Trading Update

 

Arden is today issuing a trading update in respect of the six-month period ended 30 April 2020.

 

Arden made a good start to the six-month trading period despite it encompassing the elevated political uncertainty around Brexit and then the General Election. Trading towards the end of the period has been impacted by the significant global market declines in reaction to the COVID-19 pandemic.

 

Compared to the performance in the six months ended 30 April 2019, we anticipate materially higher corporate finance revenues, higher retainer levels but lower equity commissions. The equity trading operation suffered material losses as markets fell in response to COVID-19.

 

The Board has implemented steps to reduce the Company's cost base. As a result, the Company's current annual cost base is anticipated to be more than 25% lower than last year. The measures taken include salary and fee sacrifices for all Board members and certain senior employees of in excess of 40% of salary; salary sacrifices for all other employees; the furloughing of a number of staff and the cancellation or deferral of all discretionary expenditure. Arden will also defer the payment of VAT in line with the government's proposals. The Board will continue to take action to reduce costs and minimise the financial impact of the uncertainty caused by COVID 19.  

 

Before taking into account the equity trading book losses, Arden expects to report a profit for the six-month period. After taking into account the equity trading book losses, Arden expects to report a reduced loss for the period compared to the prior year.

 

The Company has a strong balance sheet, with cash and cash equivalent resources well in excess of its regulatory requirements.   

 

Operationally, we responded to COVID-19 promptly and successfully implemented a comprehensive remote working capability, which has enabled us to ensure both the wellbeing of our staff and the ability to continue servicing our clients as normal. The Company is fully operational and continues to operate as normal. Due to the quality and flexibility of our people and the strengths of our business, our ability to attract and win new high-quality corporate clients remains strong. We continue to sign up quality clients and have a good pipeline going forward.

 

We are working closely with our corporate clients to assess the disruption caused by COVID-19 and, where possible, assist them in protecting their businesses and continuing to implement their strategies. Our aim is to fully support all corporate and institutional clients during these unprecedented times.

 

Mark Ansell, Chairman, commented:

 

"The COVID-19 crisis has presented unprecedented challenges to our business. However, it remains in a strong financial position and we have taken the necessary actions to enable us to confront the current market environment without harming our ability to fully service our clients. The Board is indebted to the Company's employees for their hard work and ongoing support in light of these challenges.

 

The Board's priorities remain to protect the Company's balance sheet and to deliver on our stated growth strategy."

 

 

For further information, please contact:

 

Arden Partners plc

 

020 7614 5900

Donald Brown - Chief Executive Officer

James Reed-Daunter - Executive Director

Steve Douglas - Group Finance Director

 

GCA Altium Limited (NOMAD)

 

020 7484 4040

Tim Richardson

 

 

Notes for editors:

 

Arden is a dedicated corporate adviser and multi-service stockbroker to small and mid-cap companies in the UK and their investors.

 

The absolute core of our business is the effective management of the needs of our significant and growing base of corporate clients, and the effective support of their relationships with existing and potential shareholders. 

 

These relationships are enhanced by the quality of our corporate finance advice and industry research, and the strong market presence of our sales and trading teams.

 

Our corporate finance capabilities encompass M&A, corporate finance advisory, broking and Sponsor and NOMAD services. We represent our clients in private transactions and AIM and Main Market share issues.

 

Our research is designed to be sector focused, concentrating on top down thematic trends which highlight companies giving investors an exposure to the real growth areas of the small-cap and AIM markets.

 

It is the job of the sales team to keep institutions abreast of these themes and stock ideas. When there is a requirement for our corporate clients to raise money to fulfil their growth ambitions, the sales team is in a strong position to effect this, with its entrenched relationships with the UK institutional and non-institutional markets.

 

Our market making and trading teams provide liquidity in the shares of our corporate clients. We also trade the shares of non-client corporates on behalf of institutions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKKBNBBKDQQN
Date   Source Headline
5th Apr 201210:23 amRNSForm 8.3 - Arden Partners plc
4th Apr 20124:00 pmRNSForm 8 (OPD) Arden Partners Plc
3rd Apr 201210:57 amRNSForm 8 (OPD) Arden Partners plc
30th Mar 201211:00 amRNSForm 8.3 - Arden Partners (Offeree)
30th Mar 201210:51 amRNSForm 8.3 - Arden partners
29th Mar 201212:46 pmRNSResult of AGM
29th Mar 201211:00 amRNSAGM Statement and Commencement of Offer Period
29th Mar 20127:00 amRNSEBT Disposal and Transfer and TVR
13th Mar 201210:03 amRNSArden Partners strengthens the team
29th Feb 201211:00 amRNSTotal Voting Rights
28th Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
27th Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
23rd Feb 20126:00 pmRNSAnnual Report and Accounts
22nd Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
17th Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
10th Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
6th Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
3rd Feb 201211:50 amRNSForm 8.5 (EPT/NON-RI)
31st Jan 201211:36 amRNSHolding(s) in Company
30th Jan 201210:51 amRNSHolding(s) in Company
27th Jan 20121:04 pmRNSHolding(s) in Company
24th Jan 201211:50 amRNSForm 8.5 (EPT/NON-RI)
19th Jan 201211:56 amRNSForm 8.5 (EPT/NON-RI)
17th Jan 201211:50 amRNSForm 8.5 (EPT/NON-RI)
16th Jan 201211:50 amRNSForm 8.5 (EPT/NON-RI)
30th Dec 201111:54 amRNSDirectorate Change
21st Dec 20117:00 amRNSPreliminary results for the year ended 31 October
3rd Nov 20112:30 pmRNSTrading Update
4th Oct 20114:29 pmRNSDirector's dealing
4th Oct 20112:30 pmRNSTotal Voting Rights
14th Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
9th Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
8th Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
7th Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
7th Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
7th Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
2nd Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
1st Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
1st Sep 201111:50 amRNSForm 8.5 (EPT/NON-RI)
31st Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
30th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
30th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
26th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
25th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
23rd Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
23rd Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
22nd Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
18th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
18th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)
15th Aug 201111:50 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.